Key information

🔎 Fund Overview

Quince Therapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on advancing precision therapeutics for debilitating and rare diseases. The Company is focused on novel therapeutic approaches to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. The Company’s lead compound, NOV004, is a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. NOV004 is designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing. The Company's discovery pipeline is potentially applicable across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases.